ðŸ§
Clinical Trial Compass
Am I eligible?
Pricing
About
Sign in
Back to search
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD (NCT05722912) | Clinical Trial Compass
APPROVED_FOR_MARKETING
Not Applicable
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
Plain-language summary
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
Trial details
NCT ID
NCT05722912
Sponsor
Incyte Corporation
Sponsor type
INDUSTRY
Study type
EXPANDED_ACCESS
View on ClinicalTrials.gov
More Graft-versus-host Disease (GVHD) trials